Boulder biotech Nivalis sees shares rise in IPO
Stock in bIotech drug developer Nivalis Therapeutics Inc. jumped 6.5 percent on its first day of public trading Wednesday, closing at $14.92 per share.
The Boulder-based company generated $77 million from sales of 5.5 million shares in its IPO.
Nivalis stock (Nasdaq: NVLS) debuted at $14 and rose as high as $17.89 in mid-day trading before settling to its closing price.
The company, formerly N30 Pharmaceuticals, is developing a cystic fibrosis treatment as its leading project.
It plans to useā¦
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Greg Avery Source Type: news
More News: Biotechnology | Cystic Fibrosis | Health | Health Management | Hospital Management | Hospitals